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Body mass index correlates positively  
with insulin resistance and secretion  
but inversely with insulin sensitivity  
in gestational diabetes
ABstrAct 
Background. to assess fasting c-peptide and insulin 
indices using homeostatic model assessment (HOMA) 
in gestational diabetes mellitus (GDM). 
Methods. Gestational diabetes mellitus (n = 64, age: 
27.02 ± 0.53 years, BMI: 26.3 ± 0.5 kg/m2; mean ± 
sEM) and normal glucose tolerance NGt (n = 56, age: 
26.11 ± 0.55 years, BMI: 24.4 ± 0.4 kg/m2; mean ± 
sEM) screened according to WHO 2013 criteria. Glucose 
was measured by oxidase method whereas fasting 
insulin and c-peptide by ELIsA. HOMA-Ir, HOMA-B and 
HOMA-%s were calculated.
results. c-peptide was found higher in GDM compared 
to NGT without any significant difference (P = 0.465). 
Fasting insulin (P = 0.063) and HOMA-IR (P < 0.001) 
were significantly higher while HOMA-B (P = 0.015) 
and HOMA-%S (P = 0.012) were significantly lower in 
GDM than those of NGt. BMI, bad obstetric history, 
multiparity and blood glucose were higher (P ≤ 0.05) 
in GDM while age, duration of gestation, family history 
of DM did not differ (P = NS). C-peptide (0.185 ± 0.06 
vs 0.331 ± 0.44; P < 0.05), fasting insulin (4.88 ± 0.74 
vs 10.37 ± 0.74; P < 0.01) and HOMA-IR (1.04 ± 0.14 vs 
2.48 ± 0.18; P < 0.011) as well as HOMA-B were found 
lower in GDM having BMI < 23 kg/m2 than those of 
GDM with BMI ≥ 23. conversely, HOMA-%s (115.52 ± 
14.63 vs 50.62 ± 3.39; P < 0.011) was higher in the 
subgroup with BMI < 23 than the rest. Fasting blood 
glucose (FBG) (P < 0.01) and fasting insulin (P < 0.05) 
were independent predictors for GDM.
conclusions. Fasting c-peptide did not differ between 
GDM and NGt. BMI was positively related with resist-
ance and secretion of insulin but inversely with sensitiv-
ity. HOMA model analyses revealed decreased insulin 
sensitivity and secretory capacity in GDM than NGt. 
(clin Diabetol 2021; 10; 3: 270–275)
Key words: GDM, Insulin, c-peptide, HOMA Ir,  
HOMA B & HOMA-%s
Introduction
Pregnancy exerts various physiologic adaptations 
to maintain normal glucose homeostasis. b-cell needs 
to compensate for the physiologic insulin resistance 
by increasing the secretion of insulin [1]. An insuf-
ficient compensatory response will lead to gestational 
diabetes mellitus (GDM). GDM if not treated results 
in various complications which poses the mother and 
child at high risk of long-term morbidity [2]. However, 
many other factors, such as genetic, environmental and 
autoimmune factors, are thought to be involved in the 
development of GDM [3].
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GDM is commonly believed to be primarily associ-
ated with insulin resistance (IR). In normal pregnancy 
(NGT, normal glucose tolerance), dysglycemia does not 
develop because of increased compensatory insulin 
secretion. If this compensatory mechanism fails, IR 
becomes predominant and GDM may develop [4–6]. 
However, IR alone is not sufficient to cause diabetes [7]. 
Thus, it is quite reasonable to assume that GDM patients 
are likely to have both defective insulin secretion and IR. 
However, observations on insulin secretion and its role in 
GDM are inconclusive. For instance, while some research-
ers have shown deficient insulin secretion in response 
to oral or intravenous glucose [8], others have found 
comparable or even higher insulin responses in women 
with GDM [5, 9]. In Asians, the pancreatic b-cell mass is 
relatively smaller compared to Western population, hence 
the insulin secretion is lower [8, 10]. Morkrid et al. [10] 
observed that the South Asian pregnant women lacks 
b-cell adaptation compared to Western Europeans. 
The physiology of C-peptide makes it appropri-
ate for assessing insulin secretion as it is secreted in 
equimolar amounts. The best method to determine 
prehepatic insulin secretion noninvasively is peripheral 
venous C-peptide concentrations [11]. Among various 
indices for measurement of insulin sensitivity/ resist-
ance, we have employed the homeostasis model assess-
ment (HOMA) model, which correlates well with gold 
standard clamp techniques [12]. It has been observed 
earlier that HOMA-B index is lower in GDM women 
of South Asia [8, 10]. This study measured fasting C-
peptide as a marker of insulin secretory capacity and 
compared it with insulin indices using HOMA model 
between GDM and NGT. 
Materials and methods
study design and sample
This study enrolled 64 women with GDM (age: 
27.02 ± 4.26 years, BMI: 26.38 ± 4.75 kg/m2; mean ± SD) 
and 56 women with NGT (age: 26.11 ± 4.13 years, 
BMI: 24.38 ± 3.59 kg/m2; mean ± SD) screened by 
3-sample 75-gm oral glucose tolerance test (OGTT) 
according to WHO 2013 criteria for GDM. Women 
irrespective of their duration of gestation with sin-
gleton pregnancy attending in the Department of 
Endocrinology, BSMMU were screened and enrolled 
consecutively. Women with prior history of DM were 
excluded from the study.
clinical, demographic and laboratory data
It was a prospective observational study done from 
April, 2018 to February, 2019. The research protocol 
was approved by the Institutional Review Board (IRB) 
prior to commencement of this study. After recording 
clinical data in the case record form, OGTT was per-
formed following an overnight fast. Study subjects were 
included as GDM or NGT on the basis of WHO 2013 
diagnostic criteria. Fasting venous blood (6 ml) was 
collected for measurement of C-peptide and insulin. 
Serum was preserved at –80° C until assay.
Oral glucose tolerance test (OGtt)
WHO (2013) recommend a 75g OGTT and the diag-
nosis of GDM are made irrespective of weeks of gesta-
tion when any one or more of the following plasma 
glucose (PG) criteria are fulfilled (Table 1). 
Analytic method 
Plasma glucose was analyzed by glucose oxidase 
method by Dimension EXL 200 Integrated Chemistry 
System (Siemens, Germany) on the same day of collec-
tion. Serum insulin levels were measured by chemilumi-
nescent immunoassay method using Access Immunoas-
say System (REF: 33410), Beckman Coulter, Inc., USA. 
Quantitative determination of serum C-peptide levels 
was done by two-site chemiluminnescent immunomet-
ric assay using Immulite 2000 System Analyzers (Cat. 
No. L2KPEP2), Siemens, Inc., Germany. The coefficient 
variances (CV) for glucose were 2.03% for low level 
values and 2.08 % for high values level where intra 
assay CV for insulin was 2.54%. Intra assay CV for 
C-peptide was 2.34%.
Assessment of insulin secretion  
nd sensitivity index
Insulin resistance and secretion were calculated by 
the equations of HOMA model described by Matthews 
et al. [12].
statistical analysis
Data were analyzed using SPSS version 23.0. 
Qualitative data were expressed as frequencies or 
percentages. Assessment of normality of quantitative 
data was done by Shapiro-Wilk test. All the quantitative 
data were found normally distributed and expressed as 
mean ± SEM. Among subgroups made on the basis of 
clinical and metabolic (hormonal and derived insulin 
table 1. WHO 2013 criteria for diagnosis of GDM [13]
time point of OGtt GDM DM in pregnancy
0-hour PG 5.1–6.9 mmol/L ≥ 7.0 mmol/L
1-hour PG ≥ 10.0 mmol/L –
2-hour PG 8.5–11.0 mmol/L ≥ 11.1 mmol/L 
DM — diabetes mellitus; GDM — gestational diabetes mellitus;  
OGTT — oral glucose tolerance test; PG — plasma glucose
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indices) findings, comparison was done by chi-square 
test and independent sample t-test. Correlation among 
BMI, C-peptide, insulin indices and derived variables 
were calculated by Pearson’s correlation test. Logistic 
regression analysis was done to determine the predic-
tive association of BMI and insulin indices in pregnant 
women with or without GDM. P value < 0.05 was 
considered as statistically significant.
Results
In this study we investigated the secretory capacity 
of islet cells by measurement of fasting C-peptide in 
GDM as well as NGT and compared between these two 
groups. Also fasting glucose and insulin indices were 
measured and compared. 
Table 2 depicts demographic variables (mean + SEM 
or %). Body weight (63.11 ± 1.47 vs 58.83 ± 1.23; P = 0.03); 
BMI (26.3 ± 0.5 vs 24.4 ± 0.4 kg/m2, P = 0.011), mul-
tiparity (41 vs 22, P = 0.007) and bad obstetric history 
(16 vs 7, P = 0.055) were statistically and significantly 
higher in the GDM group than in those with NGT while 
other variables, i.e., age (27.02 ± 0.53 vs 26.11 ± 0.55 
years, P = 0.239), gestational age (23.08 ± 1.23 vs 20.50 ± 
± 1.24 weeks, P = 0.146), family history of diabetes 
(18 vs 20, P = 0.373), didn’t show any remarkable 
difference.
As displayed in Table 3, all the glucose values were 
significantly higher in GDM than in NGT (FBG: 5.27 ± 
± 0.08 vs 4.44 ± 0.05, P < 0.001; 01 hr blood glucose: 
9.93 ± 0.22 vs 7.70 ± 0.15, P < 0.001; 2 hr blood glu-
cose: 8.43 ± 0.21 vs 6.53 ± 0.15, P < 0.001). Fasting 
insulin (9.431 ± 0.63 vs 7.557 ± 0.72, P 0.063) and 
HOMA IR (2.24 ± 0.17 vs 1.49 ± 0.13, P 0.001) were 
significantly higher while HOMA B (120.56 ± 10.42 
vs 180.64 ± 22.81, P 0.015) and HOMA-%S (61.76 ± 
4.82 vs 122.69 ± 24.88, P 0.012) were significantly 
lower in GDM than in NGT. C-peptide did not show 
any significant difference between the two groups, 
but was higher in the GDM than in NGT (0.34 ± 0.07 
vs 0.26 ± 0.06, P = 0.465). 
Table 4 shows the comparisons of various facets of 
insulin indices between BMI subgroups of GDM divided 
by the cutoff at 23 kg/m2. C-peptide (0.185 ± 0.06 vs 
0.331 ± 0.44; P < 0.05), fasting insulin (4.88 ± 0.74 vs 
10.37 ± 0.74; P < 0.01) and HOMA IR (1.04 ± 0.14 vs 
2.48 ± 0.18; P < 0.011) as well as HOMA B were found 
lower in the subgroup having BMI < 23 kg/m2 than in 
those with BMI ≥ 23. Conversely, HOMA-%S (115.52 ± 
14.63 vs 50.62 ± 3.39; P < 0.011) was higher in the 
group with BMI < 23 than in women with BMI ≥ 23.
Table 5 illustrates the predictability of different 
variables for development of GDM. Only FBG (P < 0.01) 
and fasting insulin (P < 0.05) showed significant pre-
dictive association. However BMI, family history of DM 
and bad obstetric history (BOH) (P < 0.07) also had 
a near-significant level of predictive association.
Discussion
We designed this study to explore the relationship 
of insulin secretion, resistance and sensitivity in GDM. It 
clearly demonstrated that fasting C-peptide indicating 
insulin secretion does not differ significantly between 
GDM and NGT despite a higher corresponding blood 
glucose and higher BMI in the former group. However, 
insulin secretion was found higher in GDM, with higher 
BMI reflecting altered potential of insulin secretion and 
activity in GDM irrespective of glycemic status and obe-
sity. GDM patients with higher BMI showed increased 
insulin resistance and secretion, but decreased insulin 
sensitivity, whereas lean GDM mothers had decreased 
table 2. Demographic characteristics of studied subjects
Variable Population p
GDM (n = 64) NGt (n = 56)
Age [years]a 27.02 ± 0.53 26.11 ± 0.55 0.239
Body weight [kg]a 63.11 ± 1.47 58.83 ± 1.23 0.03
BMI [kg/m2]a 26.3 ± 0.5 24.42 ± 0.4 0.011
Weeks of gestation at admission [weeks]a 23.08 ± 1.23 20.50 ± 1.24 0.146
SBP [mm Hg]a 103.98 ± 1.64 99.91 ± 1.46 0.070
DBP [mm Hg]a 66.56 ± 0.98 65.09 ± 0.92 0.279
Multiparityb 41 (64.06%) 22 (39.29%) 0.007*
Bad obstetric historyb 16 (25.0%) 7 (12.5%) 0.055*
Family history of DMb 18 (28.13%) 20 (35.1%) 0.373*
BMI — body mass index; DBP — diastolic blood pressure; FH — family history of DM in 1st degree relatives; GDM — gestational diabetes mellitus;  
NGT — normal glucose tolerance; SBP — systolic blood pressure; aExpressed as [mean ± SEM]; bExpressed as [N (95%]; p-value calculated by independent 
t-test and *expressed as p value calculated Chi-square test
Tania Tofail et al., BMI predicts gestational diabetes
273
resistance and secretion, but significantly increased 
sensitivity of insulin. Therefore other possible factors 
need investigation to explore the phenomenon of GDM 
in lean mothers. 
Characteristics of the subjects were statistically 
similar except for BMI between the groups of GDM 
and NGT. A remarkable observation of this study is that 
there was no significant difference in fasting C-peptide 
levels between GDM and NGT. This finding is consist-
ent with the observations by some other investigators 
where basal C-peptide did not vary significantly be-
tween the two groups [14]. Higher insulin secretion and 
higher insulin resistance along with low sensitivity was 
observed in GDM patients compared with  women with 
NGT. However, insulin resistance and secretion were 
higher and insulin sensitivity was lower in relatively 
obese mothers than their lean counterparts in the GDM 
group. On the other hand, in the face of lower BMI, lean 
GDM mothers had lower insulin resistance and insulin 
secretion but higher insulin sensitivity. Nevertheless, 
both the groups have expressed GDM. On the one hand, 
GDM patients had higher insulin secretion and resist-
ance, but higher C-peptide than those with NGT; on 
the other hand, lean GDM mothers had low C-peptide, 
low insulin resistance, but higher insulin sensitivity than 
obese GDM patients. Therefore, unless other factors 
are involved, it is unlikely that GDM mothers of both 
table 3. Fasting glucose, insulin, c-peptide and insulin indices in GDM and NGt
Variable Population P
GDM NGt
FBG [mmol/mL]a 5.27 ± 0.08 4.44 ± 0.05  < 0.001
1 hr BG [mmol/mL]a 9.93 ± 0.22 7.70 ± 0.15  < 0.001
2 hr BG [mmol/mL]a 8.43 ± 0.21 6.53 ± 0.15  < 0.001
Fasting insulin [µIU/mL]a 9.431 ± 0.632 7.557 ± 0.728 0.063
C-peptide [ng/mL ]a 0.34 ± 0.07 0.26 ± 0.06 0.465
HOMA IRa 2.24 ± 0.17 1.49 ± 0.13  < 0.001
HOMA Ba 120.56 ± 10.42 180.64 ± 22.81 0.015
HOMA-%Sa 61.76 ± 4.82 122.69 ± 24.8 0.012
GDM — gestational diabetes mellitus; NGT — normal glucose tolerance; HOMA-IR — homeostasis model assessment of insulin resistance; HOMA-B — ho-
meostasis model assessment of b-cell function; HOMA-%S — homeostasis model assessment of insulin sensitivity
Number of subjects for C-peptide: GDM = 36, NGT = 26
aExpressed as [mean ± SEM]; p-values calculated by independent samples t-test
table 5. Binary logistic regression
Variables in the equation B sE P
Age –0.034 0.115 0.765
BMI [kg/m2] 0.314 0.173 0.070
Gestational week –0.044 0.045 0.328
Systolic BP –0.018 0.035 0.601
FBG –5.300 1.587 < 0.001
Fasting Insulin –0.457 0.183 0.013
C-peptide –0.736 1.204 0.541
Family history of DM –2.079 1.099 0.059
Bad obstetric history 2.702 1.479 0.068
Multiparity –2.093 1.341 0.118
Constant 26.077 9.448 0.006
GDM population is distinct from NGT population (P = 0.006)
table 4. Insulin indices in GDM according to BMI categories (23 kg/m2)
Variables Groups P
BMI < 23 kg/m2 (n = 9) BMI ≥ 23 kg/m2 (n = 53)
C-peptide [ng/mL] 0.185 ± 0.06 0.331 ± 0.44 0.028
Fasting insulin [µIU/mL] 4.88 ± 0.74 10.37 ± 0.74  < 0.001
HOMA-IR 1.04 ± 0.14 2.48 ± 0.18  < 0.011
HOMA-B 89.04 ± 22.01 127.09 ± 11.61 0.146
HOMA-%S 115.52 ± 14.63 50.62 ± 3.39  < 0.011
Data were expressed as mean ± SD
Comparison between groups done by Student t-test
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the groups would develop glycemic intolerance. It can 
also be mentioned that higher glucose level in GDM did 
not proportionately influence the secretion of insulin 
or appeared the outcome of insulin resistance in GDM 
when compared to NGT mothers. Both groups had 
significantly higher BMI. This also does not seem to be 
merely attributable to only higher BMI in GDM; because 
insulin sensitivity as well as insulin resistance and secre-
tion significantly differed between lean and obese GDM 
mothers which diminished the possibility of stronger 
influence of glucose and BMI over the aberration of 
insulin activity in GDM. Hence, it is again pertinent to 
think that other factors, such as environmental and 
hormonal factors, genetic aberrance and ethnic influ-
ences, are important in our population. Apropos of 
this, our group has observed under pilot scheme that 
there is genetic polymorphism of TCF7L2 in our GDM 
mothers which is higher in frequency in lean and young 
mothers. Some other studies in broader scale have also 
observed genetic aberration among GDM mothers of 
Southeast Asian population [15]. The possibility that 
there is a shared gene causing glycemic intolerance 
expressed as GDM during pregnancy among the young 
and low BMI mothers should be investigated. We are 
planning to analyze the frequency of genetic alteration 
to find potentially relevant associations. 
BMI has a strong influence on IR in GDM. Consistent 
with another study, GDM women with higher BMI (≥ 23 
kg/m2) had decreased insulin sensitivity and significantly 
increased insulin resistance [16]. Interestingly, in women 
with lower BMI (< 23 kg/m2), there was statistically 
significant and markedly decreased C-peptide concen-
tration. This implies GDM development in lean women 
might be primarily related to poor insulin secretory 
capacity. Considering the similarity of GDM pathology 
with the pathogenesis of type 2 diabetes, it has been 
postulated that lower insulin secretory capacity is an 
important risk factor for development of type 2 diabetes 
in non-obese Asians [8]. This study clearly illustrates the 
role of b-cell dysfunction in lean GDM women. It might 
indicate that other factors are important for high preva-
lence of GDM. As mentioned above, our GDM Study 
group has also observed some genetic aberrations in 
GDM and preponderance in lean and young GDM.
IR and impaired b-cell function are the central 
pathogenic mechanisms for developing GDM [1]. 
Higher IR in GDM was also reflected in a recent work 
of our GDM study group, BSMMU [17]. Nevertheless, 
insulin secretory capacity measured by HOMA-B in 
this study was much lower than the findings of other 
authors [18]. This variance may also explain the onset 
of GDM despite lower IR even in non-obese younger 
mothers of our population.
This study evaluated insulin resistance with fasting 
insulin and HOMA-IR values and found those values to be 
significantly higher in GDM than in NGT. Insulin secretory 
index HOMA-B was significantly lower in GDM than NGT 
mothers, along with lower insulin sensitivity as meas-
ured by HOMA-%S. Some investigators suggested that 
GDM is a defect of islet beta cell functions and failure to 
increase insulin secretion in response to increased IR dur-
ing pregnancy [19]. Present findings are consistent with 
their reports, that GDM is due to both reduced insulin 
secretion and enhanced IR [6, 19]. We have measured 
exogenus glucose disposal using sequential insulin infu-
sions with the euglycemic glucose clamp technique and 
erythrocyte insulin binding. It is worth mentioning that 
high fasting serum insulin levels in GDM reported in our 
study are also in agreement with previous studies [1, 8]. 
Higher fasting insulin level is known to be an established 
indicator of IR [20].
To summarize, fasting C-peptide does not differ 
significantly between women with GDM and NGT. There 
is insulin resistance in GDM expressed in the form of 
higher insulin than that in NGT. This is also true even 
when there is undetectable secretion of C-peptide by 
pancreas in the face of abnormally higher glucose in 
GDM. In present study, HOMA model analyses revealed 
decreased insulin sensitivity and secretory capacity in 
GDM compared with that observed in NGT, and the for-
mer was more prominent in overweight GDM whereas 
the latter in lean or normal-weight women with GDM. 
Present study investigated C-peptide and fasting insulin 
levels and was unable to take into account the effect 
of other factors associated with GDM. Pre-pregnancy 
BMI could not be used for comparison between the 
study subjects. Owing to the cross-sectional nature no 
causal inference could be drawn.
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